Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled teicoplanin for persistent Staphylococcus aureus infection in cystic fibrosis
2023-000005-12Phase 2Active
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of teicoplanin in Staphylococcus aureus infection, sponsored by Azienda Ospedaliera Universitaria Integrata Verona. Primary endpoint: Safety and tolerability of inhaled teicoplanin. Started Jan 2023; status: active.
02
Drugs
teicoplanin
03
Conditions
Staphylococcus aureus infection
Beyond the preview
Go deeper on 2023-000005-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-000005-12.